摘要
目的了解程序性死亡受体1(programmed death-1,PD-1)/程序性死亡受体配体1(programmed death-ligand 1,PD-L1)抑制剂联合血管内皮生长因子(vascular endothelial growth factor,VEGF)/血管内皮生长因子受体(vascular endothelial growth factor receptor,VEGFR)抑制剂在晚期难治性结直肠癌中应用的现状。方法检索近年来国内外相关研究的文献并进行综述。结果免疫检查点PD-1/PD-L1的发现及其抑制剂的临床应用改变了晚期实体瘤治疗的格局,但PD-1/PD-L1抑制剂对微卫星错配修复完整型肿瘤疗效不佳,晚期结直肠癌大部分属于该类型。PD-1/PD-L1抑制剂与VEGF/VEGFR抑制剂联合应用可以增强它在晚期难治性结直肠癌中的作用,其相互作用的机制和临床疗效正在不断被证实。结论PD-1/PD-L1抑制剂与VEGF/VEGFR抑制剂联合应用是晚期难治性结直肠有希望的治疗策略,未来需要更多的研究进一步阐明其疗效。
Objective To analyze the status of applying programmed death-1(PD-1)/programmed death-ligand 1(PD-L1)inhibitors combined with vascular endothelial growth factor(VEGF)/vascular endothelial growth factor receptor(VEGFR)inhibitors in advanced refractory colorectal cancer.Method The relevant literature on domestic and foreign research in recent years was summarized.Results The discovery of immune checkpoint PD-1/PD-L1 and the clinical application of related drugs had changed the treatment pattern of advanced solid tumors,but PD-1/PD-L1 inhibitors had a poor efficacy in the mismatch repair prodicient tumors,and most advanced colorectal cancer belonged to this type.The combination of PD-1/PD-L1 inhibitors and VEGF/VEGFR inhibitors could enhance the therapeutic effect in the advanced refractory colorectal cancer,and their interaction mechanisms and clinical efficacy were continuously being proven.Conclusions The combination of PD-1/PD-L1 inhibitors and VEGF/VEGFR inhibitors is a promising treatment strategy for advanced refractory colorectal cancer.More studies need to be further clarified its efficacy.
作者
刘序
程黎阳
王志伟
丁洪亮
周祥武
LIU Xu;CHENG Liyang;WANG Zhiwei;DING Hongliang;ZHOU Xiangwu(Department of General Surgery,General Hospital of Southern Theater Command of The People’s Liberation Army of China,Guangzhou 510013,P.R.China)
出处
《中国普外基础与临床杂志》
CAS
2024年第7期886-891,共6页
Chinese Journal of Bases and Clinics In General Surgery
